These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27899263)

  • 41. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Temporary adalimumab dose escalation is effective in Crohn's disease patients with secondary non-response.
    Sutharshan K; Gearry RB
    J Crohns Colitis; 2013 Aug; 7(7):e277-8. PubMed ID: 23434316
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
    Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
    J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn's disease.
    Papamichael K; Karatzas P; Mantzaris GJ
    J Crohns Colitis; 2015 Jul; 9(7):589-90. PubMed ID: 25863276
    [No Abstract]   [Full Text] [Related]  

  • 45. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
    R-Grau Mdel C; Chaparro M; Mesonero F; Barreiro-de Acosta M; Castro L; Castro M; Domènech E; Mancenido N; Pérez-Calle JL; Taxonera C; Barrio J; De Francisco R; Fernández-Salgado E; Luzón L; Merino O; Oltra L; Saro C; Bermejo F; García-Sánchez V; Ginard D; Gutiérrez A; Vera I; Antón R; Ber Y; Calvet X; Gisbert JP
    Dig Liver Dis; 2016 Jun; 48(6):613-9. PubMed ID: 26992847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
    Greener T; Boland K; Milgrom R; Ben-Bassat O; Steinhart AH; Silverberg MS; Narula N
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1274-1279. PubMed ID: 34402466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.
    Dubinsky MC; Rosh J; Faubion WA; Kierkus J; Ruemmele F; Hyams JS; Eichner S; Li Y; Huang B; Mostafa NM; Lazar A; Thakkar RB
    Inflamm Bowel Dis; 2016 Apr; 22(4):886-93. PubMed ID: 26950307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease.
    Tanaka H; Kamata N; Yamada A; Endo K; Fujii T; Yoshino T; Sugaya T; Yokoyama Y; Bamba S; Umeno J; Yanai Y; Ishii M; Kawaguchi T; Shinzaki S; Toya Y; Kobayashi T; Nojima M; Hibi T;
    J Gastroenterol Hepatol; 2018 May; 33(5):1031-1038. PubMed ID: 29087616
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ustekinumab use in Crohn's disease: a Canadian tertiary care centre experience.
    Greenup AJ; Rosenfeld G; Bressler B
    Scand J Gastroenterol; 2017 Dec; 52(12):1354-1359. PubMed ID: 28885058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
    West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1122-6. PubMed ID: 18691349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease.
    Dupont-Lucas C; Sternszus R; Ezri J; Leibovitch S; Gervais F; Amre D; Deslandres C
    J Crohns Colitis; 2016 Jul; 10(7):795-804. PubMed ID: 26822611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice.
    Echarri A; Ollero V; Barreiro-de Acosta M; Fernández-Villaverde A; Hernández V; Lorenzo A; Pereira S; Carpio D; Castro J;
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):430-5. PubMed ID: 25874517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
    Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
    Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease.
    Kimura K; Yoshida A; Takayanagi R; Yamada Y
    Biopharm Drug Dispos; 2018 Jun; 39(6):283-288. PubMed ID: 29790586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
    Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P
    Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.